Taysha Gene Therapies Inc. (TSHA): Price and Financial Metrics
GET POWR RATINGS... FREE!
TSHA Stock Price Chart Interactive Chart >
TSHA Price/Volume Stats
| Current price | $2.68 | 52-week high | $26.99 |
| Prev. close | $2.62 | 52-week low | $2.33 |
| Day low | $2.55 | Volume | 266,900 |
| Day high | $2.71 | Avg. volume | 254,756 |
| 50-day MA | $4.72 | Dividend yield | N/A |
| 200-day MA | $11.27 | Market Cap | 108.66M |
Taysha Gene Therapies Inc. (TSHA) Company Bio
Taysha Gene Therapies, Inc. engages in the development and commercialization of adeno-associated viruses (AAV) based gene therapies for the treatment of monogenic diseases of the central nervous system. It also develops multiple gene therapy platforms which include AAV9 Discovery, Novel Capsid, and AAV Redosing. The company was founded by Steven Gray, Berge Minassian, and R. A. Session II on September 20, 2019 and is headquartered in Dallas, TX.
Latest TSHA News From Around the Web
Below are the latest news stories about Taysha Gene Therapies Inc that investors may wish to consider to help them evaluate TSHA as an investment opportunity.
Two Insider Moonshots Rising on Sudden BuyingBiotech insiders are among the most important investors to pay close attention to. |
The Independent Director of Taysha Gene Therapies, Inc. (NASDAQ:TSHA), Paul Manning, Just Bought 3.4% More SharesThose following along with Taysha Gene Therapies, Inc. ( NASDAQ:TSHA ) will no doubt be intrigued by the recent... |
Taysha Gene Therapies Announces Positive Safety Data from UT Southwestern-Sponsored Clinical Trial for the Treatment of CLN7 Batten Disease at 18th Annual WORLDSymposiumDALLAS, February 09, 2022--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced the presentation of clinical safety data supporting the first-generation construct at the highest dose of 1.0x1015 total vg for the treatment of CLN7 Batten disease at the |
Taysha Gene Therapies Inc. (TSHA) Recovers 20.85% From Low: Are We There Yet?Taysha Gene Therapies Inc. (NASDAQ:TSHA) concluded the trading at $7.94 on Friday, February 04 with a rise of 2.06% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $7.78 with its price kept floating in the range of $7.80 and $8.9299 on Taysha Gene Therapies Inc. (TSHA) Recovers 20.85% From Low: Are We There Yet? Read More » |
Taysha Reports Efficacy, Safety Data From High Dose Cohort For Neurological Disorder Gene Therapy TrialTaysha Gene Therapies Inc (NASDAQ: TSHA ) has reported clinical efficacy and safety data for the high dose cohort of 3.5x1014 total vg and long-term durability data across all therapeutic doses of TSHA-120 in giant axonal neuropathy (GAN). 5-point improvement was observed in the rate of decline in MFM32 score for the high dose cohort compared to natural … Full story available on Benzinga.com |
TSHA Price Returns
| 1-mo | -36.49% |
| 3-mo | -58.71% |
| 6-mo | -78.61% |
| 1-year | -88.09% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -77.00% |
| 2021 | -56.10% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...